Ivermectin effectively inhibits hepatitis E virus replication, requiring the host nuclear transport protein importin α1.
Ontology highlight
ABSTRACT: We show that ivermectin, an FDA-approved anti-parasitic drug, effectively inhibits infection with hepatitis E virus (HEV) genotypes 1 and 3 in a range of cell culture models, including hepatic and extrahepatic cells. Long-term treatment showed no clear evidence of the development of drug resistance. Gene silencing of importin-α1, a cellular target of ivermectin and a key member of the host nuclear transport complex, inhibited viral replication and largely abolished the anti-HEV effect of ivermectin.
SUBMITTER: Li Y
PROVIDER: S-EPMC8119233 | biostudies-literature |
REPOSITORIES: biostudies-literature
ACCESS DATA